Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that CS1:s third patent family has been issued in 25 European countries following a completed validation and registration process.“I am pleased to announce that our leading drug candidate CS1 has obtained a patent issued by the European Patent Office, valid in 25 European countries. This expanded patent protection, encompassing leading European pharmaceutical markets, marks yet another milestone for CS1 and is an important component is our